Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234183534> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W4234183534 endingPage "1151" @default.
- W4234183534 startingPage "1146" @default.
- W4234183534 abstract "Abstract The purpose of this study was to define, in a phase I study in leukemia, the maximally tolerated dose (MTD), major toxicities, and possible antitumor activity of Topotecan, a new topoisomerase I (topo I) inhibitor. Topotecan was delivered by a 5-day continuous infusion every 3 to 4 weeks to patients with refractory or relapsed acute leukemia, at doses ranging from 3.5 mg/m2 to 18 mg/m2 per course. Twenty-seven patients were treated, including 17 patients with acute myelogenous or undifferentiated leukemia, 7 with acute lymphocytic leukemia, and 3 with chronic myelogenous leukemia in blastic phase. Severe mucositis was the dose-limiting toxicity occurring in two of five patients treated with Topotecan 11.8 mg/m2 per course; a third patient had prolonged myelosuppression. At the MTD of 10 mg/m2 per course, 1 of 12 patients had severe mucositis and 5 had mild-to- moderate mucositis. Nausea, vomiting, diarrhea, and prolonged myelosuppression were uncommon. Three patients (11%) achieved a complete response, two (7%) had a partial response, and one (4%) had a hematologic improvement. The overall complete plus partial response rate was 19%, and 24% in acute myelogenous or undifferentiated leukemia. A novel in vitro assay that quantifies Topotecan-stabilized topo I-DNA complexes in patient samples was used, which demonstrated heterogeneity in the ability of Topotecan to interact with topo I, the intracellular target of Topotecan. This phase I study defined the MTD of Topotecan to be 10 mg/m2 by continuous infusion over 5 days every 3 to 4 weeks in patients with refractory or relapsed acute leukemia. Severe mucositis was the dose-limiting toxicity. Future studies will define the precise activity of Topotecan in different leukemia subsets, its efficacy in combination with other antileukemic drugs, and correlations between Topotecan-induced topo I-DNA complex formation and individual patient response to Topotecan." @default.
- W4234183534 created "2022-05-12" @default.
- W4234183534 creator A5011548707 @default.
- W4234183534 creator A5014102823 @default.
- W4234183534 creator A5028026524 @default.
- W4234183534 creator A5036290225 @default.
- W4234183534 creator A5045196434 @default.
- W4234183534 creator A5048402617 @default.
- W4234183534 creator A5059906905 @default.
- W4234183534 creator A5063282789 @default.
- W4234183534 creator A5072290505 @default.
- W4234183534 creator A5077488440 @default.
- W4234183534 date "1993-03-01" @default.
- W4234183534 modified "2023-10-18" @default.
- W4234183534 title "Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia" @default.
- W4234183534 doi "https://doi.org/10.1182/blood.v81.5.1146.1146" @default.
- W4234183534 hasPublicationYear "1993" @default.
- W4234183534 type Work @default.
- W4234183534 citedByCount "78" @default.
- W4234183534 countsByYear W42341835342012 @default.
- W4234183534 countsByYear W42341835342014 @default.
- W4234183534 countsByYear W42341835342020 @default.
- W4234183534 countsByYear W42341835342021 @default.
- W4234183534 crossrefType "journal-article" @default.
- W4234183534 hasAuthorship W4234183534A5011548707 @default.
- W4234183534 hasAuthorship W4234183534A5014102823 @default.
- W4234183534 hasAuthorship W4234183534A5028026524 @default.
- W4234183534 hasAuthorship W4234183534A5036290225 @default.
- W4234183534 hasAuthorship W4234183534A5045196434 @default.
- W4234183534 hasAuthorship W4234183534A5048402617 @default.
- W4234183534 hasAuthorship W4234183534A5059906905 @default.
- W4234183534 hasAuthorship W4234183534A5063282789 @default.
- W4234183534 hasAuthorship W4234183534A5072290505 @default.
- W4234183534 hasAuthorship W4234183534A5077488440 @default.
- W4234183534 hasBestOaLocation W42341835341 @default.
- W4234183534 hasConcept C126322002 @default.
- W4234183534 hasConcept C142424586 @default.
- W4234183534 hasConcept C147897179 @default.
- W4234183534 hasConcept C185592680 @default.
- W4234183534 hasConcept C202751555 @default.
- W4234183534 hasConcept C2776694085 @default.
- W4234183534 hasConcept C2776863199 @default.
- W4234183534 hasConcept C2776960273 @default.
- W4234183534 hasConcept C2777063308 @default.
- W4234183534 hasConcept C2778041864 @default.
- W4234183534 hasConcept C2778461978 @default.
- W4234183534 hasConcept C2778496288 @default.
- W4234183534 hasConcept C2780580376 @default.
- W4234183534 hasConcept C2781209748 @default.
- W4234183534 hasConcept C31760486 @default.
- W4234183534 hasConcept C55493867 @default.
- W4234183534 hasConcept C71924100 @default.
- W4234183534 hasConcept C86803240 @default.
- W4234183534 hasConcept C87355193 @default.
- W4234183534 hasConcept C90924648 @default.
- W4234183534 hasConcept C98274493 @default.
- W4234183534 hasConceptScore W4234183534C126322002 @default.
- W4234183534 hasConceptScore W4234183534C142424586 @default.
- W4234183534 hasConceptScore W4234183534C147897179 @default.
- W4234183534 hasConceptScore W4234183534C185592680 @default.
- W4234183534 hasConceptScore W4234183534C202751555 @default.
- W4234183534 hasConceptScore W4234183534C2776694085 @default.
- W4234183534 hasConceptScore W4234183534C2776863199 @default.
- W4234183534 hasConceptScore W4234183534C2776960273 @default.
- W4234183534 hasConceptScore W4234183534C2777063308 @default.
- W4234183534 hasConceptScore W4234183534C2778041864 @default.
- W4234183534 hasConceptScore W4234183534C2778461978 @default.
- W4234183534 hasConceptScore W4234183534C2778496288 @default.
- W4234183534 hasConceptScore W4234183534C2780580376 @default.
- W4234183534 hasConceptScore W4234183534C2781209748 @default.
- W4234183534 hasConceptScore W4234183534C31760486 @default.
- W4234183534 hasConceptScore W4234183534C55493867 @default.
- W4234183534 hasConceptScore W4234183534C71924100 @default.
- W4234183534 hasConceptScore W4234183534C86803240 @default.
- W4234183534 hasConceptScore W4234183534C87355193 @default.
- W4234183534 hasConceptScore W4234183534C90924648 @default.
- W4234183534 hasConceptScore W4234183534C98274493 @default.
- W4234183534 hasIssue "5" @default.
- W4234183534 hasLocation W42341835341 @default.
- W4234183534 hasOpenAccess W4234183534 @default.
- W4234183534 hasPrimaryLocation W42341835341 @default.
- W4234183534 hasRelatedWork W1976396371 @default.
- W4234183534 hasRelatedWork W2010524472 @default.
- W4234183534 hasRelatedWork W2104359420 @default.
- W4234183534 hasRelatedWork W2134193067 @default.
- W4234183534 hasRelatedWork W2243375749 @default.
- W4234183534 hasRelatedWork W2349679547 @default.
- W4234183534 hasRelatedWork W2358739720 @default.
- W4234183534 hasRelatedWork W2418382380 @default.
- W4234183534 hasRelatedWork W305459207 @default.
- W4234183534 hasRelatedWork W4234183534 @default.
- W4234183534 hasVolume "81" @default.
- W4234183534 isParatext "false" @default.
- W4234183534 isRetracted "false" @default.
- W4234183534 workType "article" @default.